Coadministration of huperzine A and ligustrazine phosphate effectively reverses scopolamine-induced amnesia in rats

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 4, 2010, Pages 449-453

  Shi, Jun ^a,c   Liu, Qingfei ^b   Wang, Yiming ^c   Luo, Guoan ^a,c  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Tsinghua University   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Coadministration; Huperzine A; Ligustrazine phosphate; Scopolamine

Indexed keywords

ACETYLCHOLINESTERASE; GLUTATHIONE PEROXIDASE; HUPERZINE A; MALONALDEHYDE; SCOPOLAMINE; SUPEROXIDE DISMUTASE; TETRAMETHYLPYRAZINE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ACETYLCHOLINESTERASE; AMNESIA; ANIMALS; CEREBRAL CORTEX; GLUTATHIONE PEROXIDASE; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE; SESQUITERPENES; SUPEROXIDE DISMUTASE;

RATTUS;

EID: 77956063341     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.07.004     Document Type: Article

References (30)

1. Armstrong R.A. Plaques and tangles and the pathogenesis of Alzheimer's disease. Folia Neuropathol 2006, 44:1-11.
2. Aydin M., özkök E., Cengiz S., Agachan B., Yilmaz H., öztürk O., et al. Changes in oxidative stress in Wistar albino rats during senescence. Adv Mol Med 2007, 3:171-175.
3. Bai D.L., Tang X.C., He X.C. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr Med Chem 2000, 7:355-374.
4. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimer's & Dementia 2007, 3:186-191.
5. Cachard-Chastel M., Devers S., Sicsic S., Langlois M., Lezoualc'h F., Gardier A.M., et al. Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. Behav Brain Res 2008, 187:455-461.
6. Chen J., Long Y., Han M., Wang T., Chen Q., Wang R. Water-soluble derivative of propolis mitigates scopolamine-induced learning and memory impairment in mice. Pharmacol Biochem Behav 2008, 90:441-446.
7. Cheng X.R., Zhang L., Hu J.J., Sun L., Du G.H. Neuroprotective effects of tetramethylpyrazine on hydrogen peroxide-induced apoptosis in PC12 cells. Cell Biol Int 2007, 31:438-443.
8. Cummings J.L. Alzheimer's disease. N Engl J Med 2004, 351:56-57.
9. Davidsson P., Blennow K., Andreasen N., Eriksson B., Minthon L., Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 2001, 300:157-160.
10. Deiana S., Harrington C.R., Wischik C.M., Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology 2009, 202:53-65.
11. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-90.
12. Fan L.H., Wang K.Z., Cheng B., Wang C.S., Dang X.Q. Anti-apoptotic and neuroprotective effects of tetramethylpyrazine following spinal cord ischemia in rabbits. BMC Neurosci 2006, 7:48-52.
13. Fan Y., Hu J., Li J., Yang Z., Xin X., Wang J., et al. Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms. Neurosci Lett 2005, 374:222-226.
14. Huang J.H., Huang X.H., Chen Z.Y., Zheng Q.S., Sun R.Y. Dose conversion among different animals and healthy volunteers in pharmacological study. Chin J Chin Pharmacol Ther 2004, 9:1069-1072.
15. Lee J.H., Park S.Y., Shin Y.W., Kim C.D., Lee W.S., Hong K.W. Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats. Brain Res 2007, 1185:246-255.
16. Lima J.A., Costa R.S., Epifânio R.A., Castro N.G., Rocha M.S., Pinto A.C. Geissospermum vellosii stembark anticholinesterase activity and improvement of scopolamine-induced memory deficits. Pharmacol Biochem Behav 2009, 92:508-513.
17. Oh J.H., Choi B.J., Chang M.S., Park S.K. Nelumbo nucifera semen extract improves memory in rats with scopolamine-induced amnesia through the induction of choline acetyltransferase expression. Neurosci Lett 2009, 461:41-44.
18. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
19. Ōyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 1984, 142:290-296.
20. Portelius E., Zetterberg H., Andreasson U., Brinkmalm G., Andreasen N., Wallin A., et al. An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 2006, 409:215-219.
21. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid Redox Signal 2007, 9:1647-1658.
22. Schliebs R., Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006, 113:1625-1644.
23. Sethi P., Jyoti A., Hussain E., Sharma D. Curcumin attenuates aluminium-induced functional neurotoxicity in rats. Pharmacol Biochem Behav 2009, 93:31-39.
24. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
25. Wang R., Yan H., Tang X.C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006, 27:1-26.
26. Xu H., Shi D.Z. The clinical applications and pharmacologic effects of Ligustrazine. Chin J Integr Tradit West Med 2003, 23:376-377.
27. Youdim M.B.H., Buccafusco J.J. CNS targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's disease. J Neural Transm 2005, 112:519-537.
28. Zhang H.Y., Tang X.C. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 2006, 27:619-625.
29. Zhang H.Y., Zheng C.Y., Yan H., Wang Z.F., Tang L.L., Gao X., et al. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chem Biol Interact 2008, 175:396-402.
30. Zhao L., Wei M.J., He M., Jin W.B., Zhao H.S., Yao W.F. The effects of tetramethylpyrazine on learning and memory abilities of mice with Alzheimer disease and its possible mechanism. Chin Pharmacol Bull 2008, 24:1088-1092.